VFA
TGTX icon

Virtus Fund Advisers’s TG Therapeutics TGTX Stock Holding History

Virtus Fund Advisers’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$343K Buy
+41,833
New +$365K ﹤0.01% 418
2014
Q3 		– Sell
-2,003
Closed -$19K – 1861
2014
Q2 		$19K Buy
+2,003
New +$12.8K ﹤0.01% 2472

Other funds holding TGTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BM
Bridger Management New York $128M AUM 9.54% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Virtus Fund Advisers's TGTX Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in TG Therapeutics (TGTX) in Q4 2017: 41,833 shares worth $343K. The stake represents ﹤0.01% of the portfolio and ranks #418 among its holdings. This is a return to the name: Virtus Fund Advisers previously reported a position in TGTX as recently as Q2 2014.

Virtus Fund Advisers first reported a position in TGTX in Q2 2014 and has held it in 2 quarters since. 109 funds tracked by Wall St. Rank hold TGTX as of Q4 2017.

  • Virtus Fund Advisers held 41,833 shares of TG Therapeutics worth $343K as of Q4 2017.
  • TG Therapeutics was a new Virtus Fund Advisers position in Q4 2017.
  • TG Therapeutics made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #418 holding.
  • Virtus Fund Advisers first reported a position in TG Therapeutics in Q2 2014 and has held it in 2 quarters since.
  • 109 funds tracked by Wall St. Rank held TG Therapeutics as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.